Terms: = Colorectal cancer AND PPARG, PPARG1, 5468, ENSG00000132170, PPARG2, NR1C3, HUMPPARG AND Prognosis
5 results:
1. The expression and clinical significance of GPR39 in colon cancer.
Wu X; Dou Y; Xu H; Jiang Z
Ir J Med Sci; 2022 Aug; 191(4):1577-1585. PubMed ID: 34586565
[TBL] [Abstract] [Full Text] [Related]
2. Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis.
Wu J; Wang Z; Jin C; Ren H; Hu Y; Yang B; Hu Y
J BUON; 2021; 26(1):101-108. PubMed ID: 33721439
[TBL] [Abstract] [Full Text] [Related]
3. pparg expression in colorectal cancer and its association with staging and clinical evolution.
Villa ALP; Parra RS; Feitosa MR; Camargo HP; Machado VF; Tirapelli DPDC; Rocha JJRD; Feres O
Acta Cir Bras; 2020; 35(7):e202000708. PubMed ID: 32813759
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome.
Pancione M; Sabatino L; Fucci A; Carafa V; Nebbioso A; Forte N; Febbraro A; Parente D; Ambrosino C; Normanno N; Altucci L; Colantuoni V
PLoS One; 2010 Dec; 5(12):e14229. PubMed ID: 21151932
[TBL] [Abstract] [Full Text] [Related]
5. colorectal cancer expression of peroxisome proliferator-activated receptor gamma (pparg, ppargamma) is associated with good prognosis.
Ogino S; Shima K; Baba Y; Nosho K; Irahara N; Kure S; Chen L; Toyoda S; Kirkner GJ; Wang YL; Giovannucci EL; Fuchs CS
Gastroenterology; 2009 Apr; 136(4):1242-50. PubMed ID: 19186181
[TBL] [Abstract] [Full Text] [Related]
